Core Viewpoint - The article discusses a significant advancement in the development of disease-modifying osteoarthritis drugs (DMOADs) through a novel drug delivery system that effectively targets diseased chondrocytes, addressing major challenges in osteoarthritis treatment [1][2]. Group 1 - A multifunctional peptide (CMP) mimicking viral glycoproteins was developed to enhance drug delivery to osteoarthritic chondrocytes, overcoming issues related to cartilage penetration, retention, and selective uptake by diseased cells [2][5]. - The research team synthesized CMP, which includes a type II collagen adhesion sequence and a cell-penetrating peptide activated by matrix metalloproteinase-13, allowing the drug-loaded micelles to adhere to cartilage and selectively target diseased chondrocytes [5]. - In mouse models of osteoarthritis, the developed micelles demonstrated longer joint retention times and higher uptake rates in diseased chondrocytes compared to unmodified micelles, indicating improved efficacy [5]. Group 2 - The drug delivery system maintained cartilage metabolic homeostasis, alleviated pathological changes associated with osteoarthritis, and improved symptoms without causing additional toxicity [2][5]. - Overall, the findings suggest that the developed nanomedicine represents a promising candidate for DMOADs and provides an efficient delivery strategy for targeting other therapeutic agents to diseased chondrocytes [2][5].

Core Viewpoint - Glioblastoma (GBM) is the most common and aggressive malignant brain tumor in adults, with a median survival of only 12-18 months post-diagnosis, and current treatments have limited efficacy in extending patient lifespan [2] Group 1: Research Development - A research team led by Professor Lin Lisen from Fuzhou University and Professor Chen Xiaoyuan from the National University of Singapore published a study in Nature Nanotechnology, introducing a biohybrid chiral hydrogel that enhances postoperative GBM therapy by multi-pronged inhibition of tumor stemness [3][5] - The biohybrid chiral hydrogel is designed for intracavitary implantation after GBM tumor resection, aiming to comprehensively regulate glioblastoma stem cells (GSC) and improve postoperative treatment outcomes [5] Group 2: Mechanism and Efficacy - The hydrogel encapsulates GSC membrane-coated nanoparticles that serve as effective decoys to neutralize chemokines targeting GSC, achieving functional blockade of GSC and hydrogel infiltration [5] - The D-type chiral biohybrid hydrogel, through geometric regulation of mechanical transduction pathways, further diminishes the stemness phenotype of GSC compared to L-type and DL-type counterparts [5] - In three orthotopic GBM models, this multi-faceted GSC stemness inhibition enhances the efficacy of a gold nanoparticle-based hydrogel scaffold sensitized radiotherapy, thereby suppressing postoperative GBM recurrence [5][6]